Home Xin泰 Medical Receives Medical Device Registration for MemoSorb® Biodegradable PFO Occluder to Help Prevent Certain Strokes

Xin泰 Medical Receives Medical Device Registration for MemoSorb® Biodegradable PFO Occluder to Help Prevent Certain Strokes

Sep 11, 2023 19:02 CST Updated 19:02
ScienTech Medical

Structural Heart Disease Interventional Medical Device R&D and Manufacturer

Shape Memory Alloy

Structural Heart Disease Medical Product R&D and Manufacturer

Pencil News, Hanxin News Joint Report, September 10, 2023 – ScienTech Medical released the "Voluntary Announcement: MemoSorb Bioresorbable PFO Occluder Product Obtains Medical Device Registration Certificate," stating that LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. announced its wholly-owned subsidiary, Shanghai Shape Memory Alloy Co., Ltd., has obtained the medical device registration certificate for the MemoSorb® Bioresorbable PFO Occluder product issued by the National Medical Products Administration of the People's Republic of China.

This product can be used to prevent strokes related to patent foramen ovale (PFO) and alleviate symptoms of related conditions, with fewer complications compared to traditional metal occluders. ScienTech Medical announced that the future sales performance of the MemoSorb® bioabsorbable PFO occluder is uncertain, depending on factors such as clinical promotion, channel expansion, changes in competitive landscape, and macro policies. The board includes Ms. Chen Juan and Ms. Zhang Yuxin, among others. The company is registered as LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.

As of September 7, 2023, the share price of ScienTech Medical was HK$28.9 per share.

Source of the announcement: http://static.cninfo.com.cn/finalpage/2023-09-10/1217819281.PDF

Disclaimer: This article was written by a robot, jointly incubated by Pencil News and Hanxin News. Industrial and commercial data provided by Qichacha, other data provided by HanGuang Suwen. The content and data in this article are for reference only and do not constitute investment advice. Please verify before use.